Antibiotic Shows Effectiveness Against Deadly Staph Infections
An antibiotic that has shown effectiveness for bacterial pneumonia also appears successful in fighting methicillin-resistant staph infections, reports a team led by Duke Health. The drug, ceftobiprole, showed similar benefit when tested against the antibiotic daptomycin to treat complicated Staphylococcus aureus bacterial infections. If approved by the FDA, ceftobiprole could provide another line of defense against a common and often deadly bacterial infection.
ACTIV-6 trials show no benefit to fluticasone furoate for COVID-19 symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no clinical benefit to taking fluticasone furoate for treatment of mild-to-moderate COVID-19 symptoms.
Intravenous Iron Treatment Provides Some Benefit to Patients with Heart Failure and Iron Deficiency
Despite numerical improvements in mortality, hospitalizations and exercise ability, data did not reach the pre-specified level of statistical significance.
Newly published research explores impact of COVID-19 on hospitalized infants
Newly published research led by the Pediatrix Medical Group and the Duke Clinical Research Institute’s Rachel Greenberg, MD, MB, MHS assessed the impact of COVID-19 on pregnant women and infants admitted to the neonatal intensive care unit (NICU). It is believed to be the largest study evaluating the prevalence of COVID-19 within a diverse neonatal population and associated hospital outcomes.
Early Dexamethasone Administration Can Reduce Death or Discharge to Hospice Among Certain Types Of COVID-19 Patients, DCRI Study Shows
Results from a Duke Clinical Research Institute study that were recently published in JAMA Network Open expand the depth of understanding of how dexamethasone can improve outcomes among patients ho
Intervention Helps Clinicians Meet Guidelines for Prescribing Diabetes, Heart Drugs
Patients who have diabetes and heart disease do best when both conditions are treated according to established guidelines, but far too many are not prescribed the effective therapies. A recent study — designed and led by the Duke Clinical Research Institute (DCRI) and an academic steering committee — found that a coordinated care approach between cardiologists and diabetes specialists resulted in more patients receiving the recommended therapies. The study was funded by Boehringer Ingelheim and Eli Lilly and Company.
EMPA-KIDNEY Trial shows benefits for CKD in broad range of patients
A recent trial of empagliflozin expanded the understanding of how the drug can slow chronic kidney disease in a wide range of patients, lowering the risk of disease progression and death from cardi
Study Confirms No Benefit to Taking Ivermectin for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between parti
Trial finds common malaria prevention regimen reduces complications of sickle cell anemia in Kenyan children
A study by the Duke Clinical Research Institute comparing three treatment methods of preventing malaria in children with sickle cell anemia (SCA) found one method reduces common complications of the disease. EPiTOMISE: Enhancing Preventive Therapy Of Malaria in Children with Sickle cell anemia in East Africa, was conducted among children with SCA in Homa Bay, Kenya, where malaria is common. It evaluated the effects of a monthly combination of sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) or a monthly combination of dihydroartemisinin-piperaquine (DP) against the standard of care in Kenya, Proguanil.
Chest Pain Patients Benefit from Precision Diagnostic Testing Approach
A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing functional tests or catheterization for low- to intermediate-risk patients with new-onset chest pain.